HF
ROIV icon

HRT Financial’s Roivant Sciences ROIV Stock Holding History

HRT Financial’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-219,191
Closed -$4.76M – 4592
2025
Q4 		$4.76M Sell
219,191
-267,053
-55% -$5.27M 0.02% 810
2025
Q3 		$7.36M Buy
486,244
+366,469
+306% +$4.54M 0.03% 506
2025
Q2 		$1.35M Sell
119,775
-141,236
-54% -$1.53M 0.01% 1113
2025
Q1 		$2.63M Buy
+261,011
New +$2.82M 0.02% 690
2024
Q1 		– Sell
-173,103
Closed -$1.94M – 2977
2023
Q4 		$1.94M Buy
+173,103
New +$1.69M 0.01% 663
2023
Q3 		– Sell
-635,470
Closed -$6.41M – 2991
2023
Q2 		$6.41M Buy
+635,470
New +$5.68M 0.06% 229
2022
Q4 		– Sell
-471,738
Closed -$1.52M – 3024
2022
Q3 		$1.52M Buy
471,738
+175,215
+59% +$678K 0.02% 711
2022
Q2 		$1.21M Buy
296,523
+56,315
+23% +$224K 0.01% 805
2022
Q1 		$1.19M Buy
+240,208
New +$1.58M 0.01% 913

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

HRT Financial's ROIV Position: Q1 2026 in Review

HRT Financial sold out of Roivant Sciences (ROIV) in Q1 2026, closing a stake of 219,191 shares — an estimated $4.76M sold.

HRT Financial first reported a position in ROIV in Q1 2022 and held it in 9 quarters. The position peaked at $7.36M in Q3 2025. 439 funds tracked by Wall St. Rank hold ROIV as of Q1 2026.

  • HRT Financial reported no remaining Roivant Sciences position as of Q1 2026 after selling out during the quarter.
  • HRT Financial sold 219,191 Roivant Sciences shares in Q1 2026, an estimated $4.76M.
  • HRT Financial first reported a position in Roivant Sciences in Q1 2022 and held it in 9 quarters.
  • HRT Financial's Roivant Sciences position peaked at $7.36M in Q3 2025.
  • 439 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.